Madrid, January 9th, 2020- PharmaMar management will be meeting with institutional investors in San Francisco during the JP Morgan Annual Healthcare Conference next week.
Madrid, January 9th, 2020- PharmaMar (MSE:PHM) management will be meeting with institutional investors in San Francisco during the JP Morgan Annual Healthcare Conference next week. Amongst discussion points will be the size and impact for the company of its new lurbinectedin licensing agreement in the US with Jazz Pharmaceuticals, future business development focus, and how the company will shape its future plans.
PharmaMar recently signed a license agreement with Jazz Pharmaceuticals, on an exclusive basis, for the marketing of lurbinectedin in the US, under which PharmaMar will receive an upfront payment of $200 million and $800 million in potential milestone payments, of which up to $250 million will be paid upon the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines.
PharmaMar is also eligible to receive up to $550 million in potential commercial milestone payments. PharmaMar will also receive incremental tiered royalties on future net sales of lurbinectedin ranging from the high teens up to 30 percent, and may receive additional payments on approval of other indications. PharmaMar retains production rights for lurbinectedin and will supply the product to Jazz.
PharmaMar’s corporate presentation is available on its website via the following link: http://pharmamar.com/
To request a meeting please contact ptill@troutgroup.com.
Legal Statement
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
Media and Investor Relations Contact
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com
Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.
Phone: +34 914444500
